Zydus moves closer to US market for Keytruda biosimilar as FDA accepts application

AI summary preview · read the full story at The Economic Times

• Zydus Lifesciences has received acceptance for its application for a biosimilar of Keytruda, a major cancer drug.
• The USFDA is expected to complete its review process by the third quarter of 2027.